发明名称 |
Composition for treatment of undifferentiated gastric cancer |
摘要 |
Disclosed are: a therapeutic agent, a kit and a treatment method for undifferentiated gastric cancer; and a pharmaceutical composition, a kit and a treatment method which are more effective on a living organism having at least one cell selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing a mutant FGFR2. A combination of a FGFR2 inhibitor and a therapeutic substance for gastric cancer is more effective on undifferentiated gastric cancer. The combination of a FGFR2 inhibitor and a therapeutic substance for gastric cancer is more effective on a living organism having at least one cell selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing a mutant FGFR2.; |
申请公布号 |
US8962655(B2) |
申请公布日期 |
2015.02.24 |
申请号 |
US200812524754 |
申请日期 |
2008.01.28 |
申请人 |
Eisai R&D Management Co., Ltd. |
发明人 |
Yamamoto Yuji |
分类号 |
A01N43/42;A61K31/47;C07D215/00;C07D215/22 |
主分类号 |
A01N43/42 |
代理机构 |
Fish & Richardson P.C. |
代理人 |
Fish & Richardson P.C. |
主权项 |
1. A method for treating undifferentiated gastric cancer, characterized by administering effective dosages of 4(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, or a pharmacologically acceptable salt thereof, and a therapeutic substance selected from the group consisting of irinotecan, paclitaxel, and pharmacologically acceptable salts thereof to a living organism. |
地址 |
Tokyo JP |